HEMOGLOBINOPATHY MARKET ANALYSIS

Hemoglobinopathy Market, by Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test), by Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia), by End User (Hospitals, Diagnostic Laboratories, Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI2801
Pages :170
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Global Hemoglobinopathy Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global hemoglobinopathy market over the forecast period. North America holds 45.1% of the market share due to the increasing prevalence of Beta Thalassemia in the region. For instance, in December 2020, according to a report published on National Center for Biotechnology Information (NCBI), stated that in the U.S., the prevalence of beta thalassemia has increased approximately 7.5% over the last 50 years.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa